Ready 8-Ks
13
Latest filing
May 07, 2026 23:59 UTC
Top materiality
0.90
Event mix
earnings ×4 · leadership ×4 · other_material ×4
Sentiment
4 pos · 1 neg · 8 neu
Latest earnings
reported 2026-Q1
-
May 07, 2026 23:59 UTC
earnings
materiality 0.75
positive
item 2.02item 9.01
Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR
Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
-
Mar 20, 2026 23:59 UTC
leadership
materiality 0.15
neutral
item 5.02
Director Wendy Yarno to retire from Iovance board at 2026 annual meeting
Wendy Yarno will retire and not stand for re-election at the June 2026 annual meeting.
-
Feb 24, 2026 23:59 UTC
earnings
materiality 0.75
positive
item 2.02item 8.01item 9.01
Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC
Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.
-
Jan 09, 2026 23:59 UTC
other_material
materiality 0.65
neutral
item 8.01item 9.01
Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3
Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.
-
Nov 06, 2025 23:59 UTC
earnings
materiality 0.70
positive
item 2.02item 9.01
Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable
Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.
-
Aug 29, 2025 23:59 UTC
other_material
materiality 0.15
neutral
item 8.01item 9.01
Iovance posts updated corporate presentation for August 2025; no specific details disclosed
Company filed an 8-K announcing a revised corporate presentation dated August 2025.
-
Aug 22, 2025 23:59 UTC
other_material
materiality 0.60
neutral
item 1.01item 9.01
Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies
Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.
-
Aug 19, 2025 23:59 UTC
regulatory
materiality 0.70
positive
item 8.01item 9.01
Iovance's Amtagvi receives Health Canada approval for advanced melanoma
Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.
-
Aug 07, 2025 23:59 UTC
earnings
materiality 0.90
neutral
item 2.02item 5.02item 9.01
Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026
Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.
-
Jul 15, 2025 23:59 UTC
leadership
materiality 0.55
neutral
item 5.02item 8.01item 9.01
Iovance appoints Corleen Roche as CFO effective August 6, 2025
Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.
-
Jul 03, 2025 23:59 UTC
leadership
materiality 0.65
neutral
item 5.02
Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO
CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.
-
Jun 13, 2025 23:59 UTC
leadership
materiality 0.65
negative
item 5.02
Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025
Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.
-
Jun 10, 2025 23:59 UTC
other_material
materiality 0.40
neutral
item 5.07
Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting
Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.